Hoba Therapeutics is developing therapeutic proteins, specifically HB-086 and HB-097, targeting neuropathic pain and sensorineural hearing loss, respectively. These proteins, derived from the neurotrophic factors meteorin and cometin, aim to provide safe and effective treatments for conditions with significant unmet medical needs.
Funding
$31M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IVMIFounders
Product
Problem
Neuropathic pain and sensorineural hearing loss represent significant unmet medical needs, affecting millions worldwide with limited safe and effective treatment options. Current treatments often fail to fully alleviate symptoms or carry substantial side effects, highlighting the need for innovative therapeutic approaches.
Solution
Hoba Therapeutics is developing novel therapeutic proteins, HB-086 and HB-097, designed to address neuropathic pain and sensorineural hearing loss, respectively. These proteins are derived from the neurotrophic factors meteorin and cometin, which play a crucial role in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways. HB-086 is in late preclinical development targeting conditions like chemotherapy-induced peripheral neuropathy (CIPN) and trigeminal neuralgia, while HB-097 is in preclinical development for ototoxic hearing loss. The company's approach aims to provide restorative treatments that are both safe and efficacious for these debilitating conditions.
Target Audience
The primary target audience includes patients suffering from neuropathic pain conditions such as chemotherapy-induced peripheral neuropathy and trigeminal neuralgia, as well as individuals experiencing sensorineural hearing loss, particularly ototoxic hearing loss.
Features
- HB-086: A therapeutic protein in late preclinical development for neuropathic pain, specifically CIPN and trigeminal neuralgia.
- HB-097: A therapeutic protein in preclinical development for sensorineural hearing loss, specifically ototoxic hearing loss.
- Utilizes meteorin and cometin, endogenous human proteins, as the basis for therapeutic development.
- Targets the underlying mechanisms of nerve cell development, growth, survival, and maintenance.